Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...
ALK licenses rights to adrenaline nasal spray, neffy from ARS Pharma for emergency treatment of allergic reactions: Hørsholm, Denmark Tuesday, November 12, 2024, 12:00 Hrs [IST] ...
Health experts have argued that UK customers are being hoodwinked by the drug firms behind the 'useless' medicines - which include Sudafed, Lemsip and Beechams.
ALK will initially focus on bringing neffy® to the markets in Europe and Canada, the world's second and third largest adrenaline autoinjector ("AAI”) markets. In both markets, the product can be added ...